These tumors generally occur at a younger age compared to conventional glioblastomas and mostly lack the molecular hallmarks of conventional glioblastoma including EGFR amplification, trisomy 7 plus monosomy 10, TERT promoter mutation, and CDKN2A/B homozygous deletion. This evidence concerns the gene CDKN2A and glioblastoma.